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Summary
Background Tight control of blood glucose concentration in people with type 1 diabetes predisposes to hypoglycaemia. 
We aimed to investigate whether day-and-night hybrid closed-loop insulin delivery can improve glucose control while 
alleviating the risk of hypoglycaemia in adults with HbA1c below 7·5% (58 mmol/mol).
Methods In this open-label, randomised, crossover study, we recruited adults (aged ≥18 years) with type 1 diabetes 
and HbA1c below 7·5% from Addenbrooke’s Hospital (Cambridge, UK) and Medical University of Graz (Graz, 
Austria). After a 2–4 week run-in period, participants were randomly assigned (1:1), using web-based randomly 
permuted blocks of four, to receive insulin via the day-and-night hybrid closed-loop system or usual pump therapy 
for 4 weeks, followed by a 2–4 week washout period and then the other intervention for 4 weeks. Treatment 
interventions were unsupervised and done under free-living conditions. During the closed-loop period, a model-
predictive control algorithm directed insulin delivery, and prandial insulin delivery was calculated with a standard 
bolus wizard. The primary outcome was the proportion of time when sensor glucose concentration was in target 
range (3·9–10·0 mmol/L) over the 4 week study period. Analyses were by intention to treat. This study is registered 
with ClinicalTrials.gov, number NCT02727231, and is completed.
Findings Between March 21 and June 24, 2016, we recruited 31 participants, of whom 29 were randomised. 
One participant withdrew during the first closed-loop period because of dissatisfaction with study devices and 
glucose control. The proportion of time when sensor glucose concentration was in target range was 10·5 percentage 
points higher (95% CI 7·6–13·4; p<0·0001) during closed-loop delivery compared with usual pump therapy 
(65·6% [SD 8·1] when participants used usual pump therapy vs 76·2% [6·4] when they used closed-loop). 
Compared with usual pump therapy, closed-loop delivery also reduced the proportion of time spent in 
hypoglycaemia: the proportion of time with glucose concentration below 3·5 mmol/L was reduced by 65% (53–74, 
p<0·0001) and below 2·8 mmol/L by 76% (59–86, p<0·0001). No episodes of serious hypoglycaemia or other 
serious adverse events occurred.
Interpretation Use of day-and-night hybrid closed-loop insulin delivery under unsupervised, free-living conditions for 
4 weeks in adults with type 1 diabetes and HbA1c below 7·5% is safe and well tolerated, improves glucose control, and 
reduces hypoglycaemia burden. Larger and longer studies are warranted.
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Introduction
Intensive insulin therapy is the standard of care in the 
management of type 1 diabetes.1 Although modern insulin 
therapy has led to a reduction in the frequency of severe 
hypoglycaemic events,2 tight glycaemic control remains a 
predisposing factor to hypoglycaemia and its effect is 
amplified by duration of the disease.3 Recurrent exposure 
to hypoglycaemia might lead to attenuated counter-
regulatory response to subsequent hypoglycaemic events 
and, ultimately, impaired hypoglycaemia aware ness.4 
Frequent hypoglycaemic episodes might have a profound 
effect on behaviour and diabetes self- management, 
adversely affecting quality of life.5
The advent of continuous glucose monitoring (CGM) 
has led to improved glycaemic control and reduced 
exposure to hypoglycaemia, including severe hypo-
glycaemia.6,7 The benefits of hypoglycaemia reduction are 
enhanced in hypoglycaemia-prone individuals when 
CGM is integrated with the threshold suspend feature of 
insulin pumps, which allows insulin delivery to be 
suspended automatically for up to 2 h when the pre-set 
glucose threshold is reached8 or predicted.9 Although 
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these technologies have been shown to reduce the 
incidence of severe hypoglycaemic events, including 
those leading to hypoglycaemic seizure or coma,10 they do 
not address the issue of variability in insulin 
requirements,11 which remains an unmet need in patients 
with type 1 diabetes.
Closed-loop insulin delivery—also known as the 
artificial pancreas—is a therapeutic approach that is 
progressing quickly. Closed-loop delivery differs from 
conventional pump therapy and threshold suspend 
technology; it has a control algorithm that autonomously 
increases and decreases subcutaneous insulin delivery in 
response to real-time sensor glucose levels.12 Results from 
randomised trials13–16 of day-and-night closed-loop use 
during unsupervised free-living conditions in children, 
adolescents, and adults have shown improved glycaemic 
outcomes, reduced risk of non-severe hypoglycaemic 
events, and positive user experience. However, outside of 
pregnancy,15 none of the studies have focused specifically 
on patients with well controlled diabetes (HbA1c <7·5% 
[58 mmol/mol]) who might have a heightened, but 
masked, risk of hypoglycaemia and glucose variability. In 
this study, we aimed to investigate whether day-and-night 
hybrid closed-loop insulin delivery—in which manual 
administration of prandial bolus was implemented by the 
user—under free-living conditions in adults with HbA1c 
below 7·5% can improve glucose control while alleviating 
the risk of hypoglycaemia, thus informing whether the 
use and reimbursement of closed-loop systems is justified 
in this particular population. 
Methods
Study design and participants
In this open-label, randomised, crossover study, we 
recruited adults (aged ≥18 years) attending diabetes 
clinics at Addenbrooke’s Hospital (Cambridge, UK) and 
Medical University of Graz (Graz, Austria). Patients were 
eligible if they had type 1 diabetes (defined according 
to WHO criteria), non-hypoglycaemic C-peptide 
concentration less than 100 pmol/L, and HbA1c less 
than 7·5%; had been using insulin pump therapy for at 
least 6 months; had knowledge of insulin self-
adjustment; and had been self-monitoring their blood 
glucose concentration at least six times per day. 
Exclusion criteria included established nephropathy, 
neuropathy, or proliferative retinopathy; total daily 
insulin dose of 2·0 U/kg or more; hypoglycaemia 
unawareness (determined by Gold score ≥4 on the basis 
of pre-study clinical records); severe visual or hearing 
impairment; pregnancy; or breastfeeding (see appendix 
for the full list of inclusion and exclusion criteria).
The study was approved by the local ethics committees 
and national competent authorities in the UK and 
Austria, and the protocol (phase 2 of APhome04 study) is 
shown in the appendix. All participants provided written 
informed consent before the start of study-related 
procedures.
Randomisation and masking
Participants were randomly assigned (1:1) to receive 
either day-and-night closed-loop insulin delivery followed 
Research in context
Evidence before this study
We searched PubMed from database inception until 
Oct 24, 2016, using the search terms “type 1 diabetes” AND 
(“artificial pancreas” OR “closed-loop”) AND (“home” OR 
“outpatient”), for reports of randomised controlled trials 
published in English only. We identified 14 randomised trials 
assessing the use of closed-loop insulin delivery outside 
hospital settings. In two randomised home studies in 
participants with mean HbA1c above 7·5% (58 mmol/mol), 
long-term (>4 week) use of closed-loop insulin delivery led to a 
significant decrease in HbA1c and improvement in mean 
glucose and proportion of time spent within, below, and above 
the glucose target range (3·9–10·0 mmol/L). However, no 
studies have so far assessed closed-loop use in non-pregnant 
adults with HbA1c below 7·5%.
Added value of this study
To our knowledge, this study is the first randomised controlled 
study in free-living adults with type 1 diabetes whose HbA1c is 
below 7·5%. We showed that, compared with usual insulin pump 
therapy, day-and-night closed-loop insulin delivery significantly 
improved overall glycaemic control while reducing the burden of 
hypoglycaemia. Beneficial effects on glycaemic outcomes 
included increased time with glucose concentration in target 
range, reduced time with glucose concentration below and 
above target range, and decreased mean glucose concentration 
and glycaemic variability. The findings of increased time in 
target range and reduced overall hypoglycaemia risks and sensor 
glucose variability were similarly observed and consistent during 
night-time and daytime periods of closed-loop use. These 
outcomes were achieved without change in total insulin 
delivered. Closed-loop application thereby provides a novel 
therapeutic approach to optimise glycaemic control in 
hypoglycaemia-prone adults with HbA1c below 7·5%. 
Closed-loop application was well tolerated in this population 
with advanced self-management skills, and might provide 
clinically significant benefits to their overall diabetes care.
Implications of all the available evidence
The use of day-and-night closed-loop insulin delivery might 
further improve glycaemic control while reducing the risk and 
burden of hypoglycaemia in adults with type 1 diabetes 
whose HbA1c is below 7·5%. Results from our study, together 
with those from previous studies in different target groups, 
support the benefits of closed-loop insulin delivery in a broad 
population with type 1 diabetes.
See Online for appendix
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by usual pump therapy with blinded CGM, or vice versa. 
Following the run-in period, the order of the two study 
periods was randomly determined with an 
automated web-based programme with locally stratified, 
randomly permuted blocks of four. Participants and 
investigators analysing study data were not masked to 
treatment allocation.
Procedures
After screening, all participants underwent a 2–4 week 
run-in period, during which they were trained to use the 
study insulin pump and CGM device, and calibrated the 
real-time CGM device according to manufacturer’s 
instructions. Compliance assessment after the run-in 
period was based on at least 10 days of CGM use in the 
past 2 weeks.
Participants then received insulin via the day-and-night 
closed-loop system (closed-loop period) for 4 weeks and 
via usual pump therapy with blinded CGM (control 
period) for 4 weeks, in the order assigned at 
randomisation, with a 2–4 week washout period in 
between. During the washout period, participants 
returned to their usual care and did not use the study 
CGM device. Identical study insulin pumps and CGM 
devices were used during the two treatment periods. 
Participants used rapid-acting insulin analogue normally 
applied in their usual clinical care. The built-in bolus 
wizard of the study insulin pump was used by participants 
during both treatment periods to calculate insulin 
boluses at mealtimes and when administering correction 
boluses. The study was done under free-living conditions 
without direct or remote supervision by clinical 
investigators. Participants were not restricted in their 
dietary intake or daily activities. Support was available at 
all times to assist participants in case of clinical or 
technical issues that arose during the study. Standard 
local hypoglycaemia and hyperglycaemia treatment 
guidelines were followed.
The FlorenceD2A closed-loop system (University 
of Cambridge, Cambridge, UK) comprised a model-
predictive control algorithm on a smartphone (Galaxy S4, 
Samsung, South Korea), which communicated wirelessly 
with a purpose-made translator unit (Triteq, Hungerford, 
UK) and the study pump (DANA-R Diabecare, Sooil, 
Seoul, South Korea) through a Bluetooth communication 
protocol (appendix). The CGM receiver (FreeStyle 
Navigator II, Abbott Diabetes Care, Alameda, CA, USA) 
was inserted into the translator, which translated a serial 
USB protocol into a Bluetooth communication protocol. 
The calculations used a compartment model of glucose 
kinetics17 describing the effect of rapid-acting insulin and 
the carbohydrate content of meals on glucose levels. 
We applied a hybrid closed-loop approach in which 
participants were required to count carbohydrates and use 
a standard bolus calculator for pre-meal boluses according 
to usual practice. The bolus calculations provided by the 
study pump’s built-in bolus calculator took into account 
carbohydrate content of meals, insulin on board, and 
entered capillary blood glucose readings. The algorithm 
was initialised by pre-programmed basal insulin rates 
downloaded from the study pump. Participants’ 
bodyweight and total daily insulin dose were entered at 
set-up. During closed-loop operation, the algorithm 
adapted itself to a particular participant. The treat-to-target 
control algorithm aimed to achieve glucose concentrations 
of 5·8–7·3 mmol/L, and adjusted the actual concentration 
depending on fasting versus postprandial status and the 
accuracy of model-based glucose predictions. Control 
Algorithm version 0.3.46 was used (University of 
Cambridge, Cambridge, UK) which, compared with that 
used in our previous study,13 included enhanced adaptation 
of insulin needs based on analysis of past performance 
and identification of the time of day when insulin needs 
are consistently lower or higher. Participants were trained 
to perform a calibration check before breakfast and 
evening meal. If sensor glucose was above capillary 
glucose by more than 3 mmol/L, participants were advised 
to recalibrate the CGM device. These instructions resulted 
from in-silico assessment of hypoglycaemia and 
hyperglycaemia risks using the validated Cambridge 
simulator.18 Safety rules limited maximum insulin 
infusion and suspended insulin delivery at sensor glucose 
at or less than 4·3 mmol/L, or when sensor glucose was 
rapidly decreasing.
During the control period, the display of the study CGM 
device was masked. Participants were allowed to use their 
own glucose monitoring devices (CGM or flash glucose 
monitoring19) if they were part of their pre-study usual 
care. The control intervention was chosen according to 
existing clinical practice and participants’ preferences.20 
The rationale for the control period was to reflect usual 
clinical practice and national reimbursement policies, and 
to compare the incremental benefits gained by closed-loop 
insulin delivery with the therapeutic modality followed by 
the participants in a pragmatic study design.
At the start of the closed-loop period, participants were 
admitted to the local clinical research facility for a training 
session, which covered starting and stopping of the closed-
loop system and troubleshooting of technical issues. If 
sensor glucose readings became unavailable, or in case of 
other system failures, participants were alerted by an 
audible alarm and the system restarted the participant’s 
usual insulin delivery rate within 30–60 min to mitigate 
the risk of insulin under-delivery and over-delivery.21 
Participants were instructed to have the low-glucose alarm 
audible at all times. The sensor glucose alarm threshold 
for hypoglycaemia was initially set at 3·5 mmol/L, but 
these settings could be later modified by the participants. 
A user feedback questionnaire was completed by 
participants at the end of the closed-loop period.
Blood samples for HbA1c and C-peptide measurements 
were taken after enrolment. Plasma C-peptide was 
measured with chemiluminescence immunoassays 
(Diasorin Liaison XL [Deutschland GmbH, Dietzenbach, 
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Germany] used in Cambridge; ADVIA Centaur [Siemens 
Healthcare Diagnostics, USA] used in Graz). HbA1c was 
measured with ion exchange high-performance liquid 
chromatography, compliant with the International 
Federation of Clinical Chemistry and Laboratory 
Medicine, at study centres (G8 HPLC Analyzer [Tosoh 
Bioscience, South San Francisco, CA, USA] in 
Cambridge; Menarini HA-8160 HbA1c auto-analyser 
[Menarini Diagnostics, Florence, Italy] in Graz).
Outcomes
The primary outcome was the proportion of time during 
the whole study when sensor glucose concentration was 
in the target range of 3·9–10·0 mmol/L. Secondary 
efficacy outcomes were proportion of time with sensor 
glucose concentration above and below target range; 
time with glucose concentration below 3·5 mmol/L, 
3·3 mmol/L (post hoc), and 2·8 mmol/L, and above 
13·9 mmol/L (post hoc) and 16·7 mmol/L; the number 
of nights and mean duration when sensor glucose was 
below 3·5 mmol/L for at least 20 min; hypoglycaemia 
burden (ie, area under the curve when sensor glucose 
concentration was less than 3·5 mmol/L; post hoc); 
mean, SD, and coefficient of variation (post hoc) of 
sensor glucose; total daily, basal, and bolus insulin dose; 
and weekly trends in glucose control and insulin 
delivery. The between-day coefficient of variation of 
sensor glucose was calculated from daily mean glucose 
values (midnight to midnight). To limit multiple 
comparison, daytime (0601 h to 2359 h) and night-time 
(0000 h to 0600 h) endpoints were calculated with data 
from the respective periods for a subset of outcomes—
proportion of time with glucose concentration in target 
range, above and below target range, below 3·5 mmol/L, 
and below 2·8 mmol/L; SD of sensor glucose 
concentration; between-day and between-night 
coefficient of variation of sensor glucose concentration; 
and area under the curve when sensor glucose 
concentration was less than 3·5 mmol/L.
Of note, two prespecified secondary outcomes will not 
be reported. We will not report time spent in target 
glucose range (3·9–10·0 mmol/L) based on subcutaneous 
glucose monitoring adjusted for sensor error during the 
entire home stay because the general consensus is that 
outcomes based on unadjusted CGM values should be 
reported.22 Additionally, low blood glucose index will not 
be reported since it is not generally well understood by 
non-specialists and is highly correlated with time with 
glucose concentration below 3·9 mmol/L.23 
Safety outcomes were severe hypoglycaemic events, 
significant ketonaemia (>3·0 mmol/L), and other adverse 
and serious adverse events. We also assessed the 
frequency and duration of use of the closed-loop system 
at home as a measure of utility outcome. 
Statistical analysis
The power calculation was based on improvements in 
time spent in glucose concentration target range. 
Assuming an SD of 18% and mean improvement of 
time spent in target range of 10%,13,24 31 participants 
were needed at the desired 80% power and α level 
of 0·05 (two-tailed). If the mean improvement was 12%, 
the required sample size was reduced to 20. We planned 
to recruit up to 34 participants, aiming for 24 participants 
to complete the study to allow for dropouts (anticipated 
dropout rate of 25% based on the investigators’ 
experience and expectation). Participants who dropped 
out of the study during the run-in period and within the 
first 2 weeks of the first treatment period were allowed 
to be replaced.
We agreed on the statistical analysis plan following 
completion of the last patient’s last visit but before the 
final dataset was reviewed and analysed. The analyses 
were done by intention to treat. Efficacy and safety data 
from all randomised participants, including those who 
dropped out, were included in the analysis. We 
compared the respective measurements obtained 
during the closed-loop period and the control period 
using a regression model that accounts for period effect. 
Log-transformed analyses were used for highly skewed Figure 1: Trial profile
31 patients invited
31 screened
31 trained on study pump 
 and continuous glucose-
 monitoring device
2 dropped out during 
 run-in period
29 randomly assigned 
14 assigned to day-and-night 
 closed-loop insulin delivery
1 dropped out
13 assigned to usual therapy
15 assigned to usual therapy
15 assigned to day-and-night 
 closed-loop insulin delivery
28 completed the study
29 included in analysis
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endpoints. Values were presented as mean (SD) or 
median (IQR) for each study period. A 5% significance 
level was used to declare statistical significance for all 
comparisons. Outcomes were calculated with GStat 
software (University of Cambridge, Cambridge, UK), 
version 2.2.4, and statistical analyses were done with 
SPSS (IBM Software, Hampshire, UK), version 23.
This study is registered with ClinicalTrials.gov, number 
NCT02727231.
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. Abbott Diabetes Care read the 
manuscript before submission. The corresponding author 
had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between March 21 and June 24, 2016, we recruited 
31 participants (figure 1). Two participants withdrew 
during the run-in period because of issues associated 
with use of the study pump. 29 eligible participants 
(17 from Cambridge and 12 from Graz) were randomly 
assigned. One participant dropped out during the first 
closed-loop period because of dissatisfaction with study 
devices and glycaemic control. Of 29 randomised 
participants, five (17%) used real-time CGM and six (21%) 
used flash glucose monitoring as part of their usual care 
(table 1; appendix).
The primary outcome of the study—the proportion of 
time during the whole study period when sensor 
glucose concentration was in the target range 
(3·9–10·0 mmol/L)—was 10·5 percentage points higher 
(95% CI 7·6–13·4; p<0·0001) during the closed-loop 
period than during the control period (65·6% [SD 8·1] 
when participants were using usual pump therapy vs 
76·2% [6·4] when they used closed-loop; table 2). 24 h 
sensor glucose and insulin delivery profiles are shown in 
figure 2. The proportion of time sensor glucose 
concentration was in the target range seemed unchanged 
over the 4 week intervention periods (appendix).
Day-and-night closed-loop insulin delivery reduced 
mean glucose concentration by 0·4 mmol/L (0·1–0·7, 
p=0·0226) compared with usual pump therapy (table 2, 
figure 3). Compared with the control period, 
day-and-night closed-loop insulin delivery reduced the 
proportion of time with glucose concentration below 
3·9 mmol/L by 50% (37–59, p<0·0001), below 
3·5 mmol/L by 65% (53–74, p<0·0001), below 
3·3 mmol/L by 70% (57–78, p<0·0001), and below 
2·8 mmol/L by 76% (59–86, p<0·0001), as well as the 
burden of hypoglycaemia (ie, area under the curve when 
sensor glucose concentration was less than 3·5 mmol/L) 
by 73% (59–82, p<0·0001). Closed-loop insulin delivery 
also reduced the number of nights when glucose 
concentration was below 3·5 mmol/L for at least 20 min 
as well as the mean duration of such periods (table 2). 
Data (n=29)
Sex
Female 15 (52%)
Male 14 (48%)
Age (years) 41 (13)
Bodyweight (kg) 72·9 (13·0)
BMI (kg/m²) 25·1 (3·0)
HbA1c (%) 6·9 (0·5)
HbA1c (mmol/mol) 51·7 (4·8)
Duration of diabetes (years) 24 (12)
Duration using pump (years) 6 (4)
Total daily insulin (U/kg/day) 0·5 (0·1)
Glucose sensor use
No previous glucose sensor use 18 (62%)
Real-time continuous glucose monitoring 5 (17%)
Flash glucose monitoring 6 (21%)
Data are mean (SD) or n (%). 
Table 1: Baseline characteristics
Closed-loop 
period (n=29)
Control period 
(n=28)
Paired difference* 
or paired ratio† 
(95% CI)
p value
Proportion of time with glucose concentration in range (%)
3·9–10·0 mmol/L‡ 76·2% (6·4) 65·6% (8·1) 10·5 (7·6 to 13·4) <0·0001
>10·0 mmol/L 20·4% (6·3) 27·4% (9·6) –6·9 (–10·2 to –3·5) 0·0003
>13·9 mmol/L 3·8% (2·6) 6·9% (3·9) –3·0 (–4·4 to –1·6) 0·0002
>16·7 mmol/L 0·9% (0·8) 2·1% (1·8) –1·2 (–1·9 to –0·6) 0·0009
<3·9 mmol/L 2·9% (2·3 to 4·0) 5·3% (3·5 to 10·0) 0·50 (0·41 to 0·63)† <0·0001
<3·5 mmol/L 1·3% (0·8 to 2·3) 3·4% (1·9 to 7·2) 0·35 (0·26 to 0·47)† <0·0001
<3·3 mmol/L 0·9% (0·5 to 1·7) 2·6% (1·3 to 5·5) 0·30 (0·22 to 0·43)† <0·0001
<2·8 mmol/L 0·3% (0·1 to 0·5) 1·0% (0·5 to 2·6) 0·24 (0·14 to 0·41)† <0·0001
AUCday <3·5 mmol/L
(min × mmol/L)
9·1 (3·7 to 18·2) 26·7 (13·1 to 65·5) 0·27 (0·18 to 0·41)† <0·0001
Mean glucose 
concentration (mmol/L)
7·9 (0·5) 8·3 (0·9) –0·4 (–0·7 to –0·1) 0·0226
SD of glucose 
concentration (mmol/L)
2·8 (0·4) 3·3 (0·5) –0·5 (–0·7 to –0·3) <0·0001
Coefficient of variation of glucose concentration
Within days (%) 35·3 (3·0) 40·3 (5·1) –5·0 (–7·1 to –3·0) <0·0001
Between days (%) 12·8 (3·3) 20·2 (4·6) –7·5 (–9·7 to –5·3) <0·0001
Sensor glucose concentration <3·5 mmol/L for at least 20 min
Number of nights 2·1 (1·0) 5·6 (3·5) –3·6 (–4·9 to –2·2) <0·0001
Mean duration of each 
episode (min)
45 (13) 75 (25) –29 (–38 to –20) <0·0001
Data are mean (SD) or median (IQR), unless otherwise stated. No significant period effect was observed. AUCday=sensor 
glucose area under the curve per day. *Unless specified otherwise, data are normally distributed and presented as mean 
difference of closed-loop period minus control period, with 95% CI for mean; a positive value indicates that the 
measurement was higher during the closed-loop period than in the control period. †Non-normally distributed data are 
presented as ratio of closed-loop data over control data, with 95% CI for ratio; a value greater than unity indicates that 
the measurement was higher in the closed-loop period than in the control period. ‡Primary outcome.
Table 2: Overall day-and-night glucose control during closed-loop and control periods based on sensor 
glucose measurements
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Compared with usual pump therapy, closed-loop insulin 
delivery reduced the proportion of time with glucose 
concentration above the target range (ie, >10 mmol/L) 
by 6·9 percentage points (3·5–10·2, p=0·0003), above 
13·9 mmol/L by 3·0 percentage points (1·6–4·4, 
p=0·0002) and above 16·7 mmol/L by 1·2 percentage 
points (0·6–1·9, p=0·0009; table 2). Moreover, all 
measures of glycaemic variability were significantly 
lower in the closed-loop period than in the control 
period: SD of sensor glucose was 0·5 mmol/L (0·3–0·7) 
lower (p<0·0001), coefficient of variation of sensor 
glucose within days was 5·0% (3·0–7·1) lower 
(p<0·0001), and coefficient of variation of sensor glucose 
between days was 7·5% (5·3–9·7) lower (p<0·0001; 
table 2). Total daily insulin was similar between study 
periods (table 3). Weekly trends in glucose control and 
insulin delivery are shown in the appendix (p 3). 
Outcomes at night time (0000 h to 0600 h) and 
daytime (0601 h to 2359 h) were in concordance with 
outcomes from the combined day-and-night period 
(table 4). Night-time use of closed-loop insulin delivery 
significantly increased the proportion of time with 
glucose concentration in target range by 17·2 percentage 
points (95% CI 12·0–22·4, p<0·0001), reduced mean 
glucose concentration by 0·4 mmol/L (0·1–0·8, 
p=0·0211), and decreased the burden of hypoglycaemia 
by 89% (80–94, p<0·0001) compared with the control 
period. SD and between-night coefficient of variation of 
sensor glucose were significantly reduced by closed-
loop insulin delivery (table 4). Daytime use of closed-
loop insulin delivery increased time spent with glucose 
concentration in the target range by 8·1 percentage 
points (95% CI 5·3–11·0, p<0·0001) and reduced the 
burden of hypoglycaemia by 61% (14–75, p=0·0001). 
Closed-loop insulin delivery significantly reduced the 
SD and between-day coefficient of variation of sensor 
glucose (table 4), in line with measured outcomes of 
night-time glycaemic variability.
Overall mean absolute relative deviation of sensor 
glucose, using capillary glucose as the reference, was 
15·3% (SD 18·2) and median absolute relative deviation 
was 10·1% (IQR 4·7–19·3), on the basis of 8447 paired 
capillary-CGM values. Sensor alarm settings were not 
altered by participants during closed-loop intervention.
No significant difference was seen in sensor glucose 
availability between study periods (97% [IQR 95–99] in 
closed-loop period vs 96% [91–97] in control period; 
p=0·10). Day-and-night closed-loop delivery was used 
for 90% (95% CI 78–89) of the closed-loop period. 
The user feedback questionnaire was fully completed 
by 26 participants, and four of the six questions 
were answered by all participants (appendix). 27 (93%) 
of 29 participants were happy to have their glucose 
levels automatically controlled by the closed-loop 
system. 20 (69%) participants stated that they spent less 
time managing their diabetes while using the closed-
loop system, but seven (24%) disagreed with this 
statement. 18 (62%) expressed fewer concerns about 
their glycaemic control while using the closed-loop 
system. 14 (48%) participants reported improved sleep 
during the closed-loop period. 23 (88%) of 
26 participants reported feeling safe while using the 
closed-loop system, and 26 (96%) of 27 would 
recommend it to others.
No serious adverse events, episodes of severe 
hypoglycaemia, or episodes of hyperglycaemia with 
ketosis were reported. Skin irritations related to sensor 
use occurred in four participants. Two participants had 
mild respiratory tract infections (one during the run-in 
period and one during the control period). One 
participant had cystitis during the closed-loop period 
and one reported allergic rhinoconjunctivitis during the 
control period. All reported adverse events were resolved 
without sequelae.
Figure 2: Median sensor glucose and insulin delivery for the 24 h duration over the study period
Median (IQR) sensor glucose concentration (A) and insulin delivery (B) during closed-loop period (solid red line 
and red shaded area) and control period (dashed black line and grey shaded area) for the 24 h duration. 
The horizontal dashed lines show the lower and upper limits of the glucose target range (3·9–10·0 mmol/L).
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Discussion
In this two-centre, open-label, randomised, crossover 
trial, we showed that, in adults with type 1 diabetes and 
HbA1c below 7·5%, day-and-night hybrid closed-loop 
insulin delivery significantly improved overall glucose 
control while reducing hypoglycaemia progressively by 
50–75% at lower glucose thresholds compared 
with usual insulin pump therapy. Beneficial effects 
on glycaemic outcomes included increased time 
spent with glucose concentration in target range 
(3·9–10·0 mmol/L), reduced time with glucose 
concentration above and below the target range, and 
decreased mean glucose concentration and glycaemic 
variability. The findings of increased time spent in 
the glucose concentration target range, reduced 
hypoglycaemia, and decreased glycaemic variability 
were similarly observed during night-time and daytime 
periods. These outcomes were achieved without change 
in total insulin delivery.
Hypoglycaemia is associated with increased morbidity 
and mortality in patients with type 1 diabetes.25 A 
reduction of at least 30% in risk of hypoglycaemia, as 
observed in our study, is considered clinically relevant.26 
Threshold and predictive low-glucose suspend insulin 
delivery systems8–10 cannot step-up insulin delivery and 
thus do not address the issue of hyperglycaemia. The 
advantage of a closed-loop system such as ours is the 
responsive, graduated modulation of insulin delivery, 
both below and above the pre-set pump regimen. This 
notion is supported by findings from our study, which 
showed that reduction in mean glucose concentration 
was accompanied by significant reduction in all the 
measured hypoglycaemia parameters. The multiplicity of 
beneficial outcomes—including increased time with 
optimum glucose control (in target range) and reduced 
time below and above target range, which were 
consistently observed during both night-time and 
daytime periods—suggests that the benefits of the 
closed-loop system can be accrued irrespective of the 
time of day in adults with HbA1c below 7·5%. The control 
algorithm used in our study had enhanced adaptive 
features and coped safely with variations in insulin 
requirements, trading variability in insulin delivery for 
consistency in glucose concentrations. Several studies 
have shown that increased glycaemic variability is 
associated with the burden of hypoglycaemia.27 Glycaemic 
variability28 and hypoglycaemia25 have both been 
associated with adverse clinical outcomes. We 
hypothesise that the significant reductions in glucose 
variability and hypoglycaemia by closed-loop insulin 
delivery in our study might have implications for clinical 
outcomes, although this hypothesis will need 
confirmation by longer and larger studies.
Compared with previous unsupervised home-based 
studies,13,16 our study revealed new findings, specifically 
in relation to the improvements of CGM-derived 
hypoglycaemia parameters. Compared with Thabit and 
colleagues’ study of closed-loop insulin delivery versus 
sensor-augmented pump therapy in patients with type 1 
diabetes and HbA1c between 7·5% and 10·0% 
(58–86 mmol/mol),13 our study had more pronounced 
relative reductions in the proportion of time with glucose 
concentration below 3·9 mmol/L (19% vs 50%) and 
hypoglycaemia burden (39% vs 73%). These differences 
might have been attributable to the use of an enhanced 
adaptive control algorithm and tight glycaemic control at 
baseline in the present study (mean screening HbA1c 
6·9% vs 8·5% in Thabit and colleagues’ study13), as well 
as differences in the control therapies between the 
two studies. The proportion of time spent with glucose 
concentration below the target range (ie, 3·9 mmol/L) 
during usual pump therapy (5·3%, IQR 3·5–10·0) was 
notably higher in our study than that in Thabit and 
colleagues’ study (3·0%, 1·8–6·1)13 but still lower than 
that in a study in adults with a mean baseline HbA1c 
of 6·7% (mean proportion of time spent with sensor 
glucose below target range 14% [SD 11]).19 Another study15 
assessed the use of closed-loop insulin delivery during 
night time in pregnant women with type 1 diabetes, 
using a control algorithm with a lower glucose setpoint 
to accommodate lower glucose targets (3·5–7·8 mmol/L) 
for this group of patients. In this study,15 use of the 
Figure 3: Individual values of mean sensor glucose and proportion of time 
spent with glucose concentration below the target range for the whole study
The size of the circles denotes the proportion of time spent with low glucose 
(<3·5 mmol/L). 
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<1%
<5%
<10%
Closed-loop period 
(n=29)
Control period 
(n=28)
Paired difference* 
(95% CI)
p value
Total daily insulin (U/day) 37·5 (13·8) 37·4 (12·6) 0·8 (–1·0 to 2·6) 0·36
Total bolus insulin (U/day) 18·6 (7·9) 20·2 (8·4) –1·1 (–2·4 to 0·2) 0·11
Total basal insulin (U/day) 18·9 (7·8) 17·2 (5·7) 1·9 (0·7 to 3·1) 0·0038
Data are mean (SD), unless otherwise stated. *Normally distributed data are presented as mean difference of 
closed-loop period minus control period, with 95% CI for mean; a positive value indicates that the measurement was 
higher in the closed-loop period than in the control period.
Table 3: Insulin delivery over 24 h period
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closed-loop system increased the primary endpoint (time 
in target range overnight) by 15 percentage points 
compared with sensor-augmented pump therapy. The 
difference between this study15 and ours is the overnight-
only use of closed-loop in the former, and the difference 
in the comparator between the two studies (sensor-
augmented pump therapy vs usual pump therapy). 
Comparability between both studies is also challenging 
because this specific group of women with type 1 diabetes 
is highly motivated, albeit over a short time period (ie, 
during pregnancy), and received intensive dietetic, 
education, and clinical support. 
The additional benefit of closed-loop insulin delivery in 
individuals with well controlled type 1 diabetes 
(ie, HbA1c <7·5%) is the reduction of the residual risk of 
complications, hypoglycaemia, and glycaemic variability, 
as well as the burden of self-management. Reduction of 
hypoglycaemic burden has benefits such as improved 
quality of life and reduced societal cost.5,29 Existing 
reimbursement criteria in several countries for CGM are 
still predominantly focused on HbA1c and might exclude 
patients with HbA1c below 7·5% because of the dearth of 
evidence showing efficacy. However, results from our 
study show efficacy in terms of both improved glycaemic 
control and reduced risk of hypoglycaemia. Thus, 
reimbursement of closed-loop technology in patients 
with HbA1c below 7·5% could be considered justifiable.
The reduction in hypoglycaemic burden in our study 
was almost identical to that in Russell and colleagues’ 
study,30 which compared 5 day use of a bihormonal 
(insulin and glucagon) closed-loop system with usual 
pump therapy in adults with type 1 diabetes. Participants 
in Russell and colleagues’ study had a baseline HbA1c of 
7·1% (SD 0·8), and lower mean glucose concentration 
and risk of hypoglycaemia during the closed-loop period 
than during usual pump therapy. The study was done 
under direct supervision during the closed-loop period 
but not during the control period. The incremental 
reduction in hypoglycaemia achieved by bihormonal 
versus single-hormone closed-loop systems needs to be 
further assessed in longer, unsupervised, head-to-head, 
randomised studies to justify the increased complexity 
and cost. A single-hormone hybrid closed-loop system 
was approved in September, 2016, by the US Food and 
Drug Administration on the basis of results from a 
3 month study31 in adolescents and adults with mean 
HbA1c of 7·4% (SD 0·9) at screening. However, this study 
was non-randomised and did not have a control group, 
and the length of study periods was not matched (2 week 
run-in phase, which was used as baseline comparator for 
a 3 month intervention).
Results from participants’ feedback indicate a high 
level of trust in the closed-loop system autonomously 
modulating their glucose concentrations, with the 
majority agreeing that the time spent on management of 
diabetes was reduced during the closed-loop period. 
However, seven (24%) of 29 participants disagreed with 
this statement, reflecting that user input is still needed 
for a hybrid closed-loop system. CGM alarms and 
connectivity issues, especially at night, might have 
negatively affected participants’ experience of the closed-
loop system. One participant withdrew from the study 
because of recurrent technical issues related to the 
closed-loop system. However, an overall positive 
endorsement of the closed-loop system was observed, 
since most participants were willing to recommend the 
closed-loop system to others.
The strengths of this study include the randomised, 
two-centre, two-country, crossover design. So far, none of 
the home-based studies of closed-loop insulin delivery 
have focused specifically on patients with HbA1c 
below 7·5% who might be early adopters of closed-loop 
Closed-loop 
period (n=29)
Control period 
(n=28)
Paired difference* or 
paired ratio† (95% CI)
p value
Night time (0000 h to 0600 h)
Proportion of time with glucose concentration in range (%)
3·9–10·0 mmol/L 82·0% (9·7) 64·5% (11·5) 17·2 (12·0 to 22·4) <0·0001
>10·0 mmol/L 14·9% (8·5) 25·4% (11·8) –10·2 (–15·4 to –5·1) 0·0004
<3·9 mmol/L 3·2% (1·6 to 4·0) 9·0% (4·6 to 15·7) 0·33 (0·24 to 0·45)† <0·0001
<3·5 mmol/L 1·1% (0·4 to 2·2) 5·4% (2·9 to 11·4) 0·19 (0·12 to 0·28)† <0·0001
<2·8 mmol/L 0·1% (0·0 to 0·6) 1·7% (0·9 to 5·7) 0·14 (0·08 to 0·26)† <0·0001
AUCday <3·5 mmol/L 
(mmol/L × min)
5·1 (1·4 to 15·5) 41·5 (21·5 to 122·8) 0·11 (0·06 to 0·20)† <0·0001
Mean glucose 
concentration (mmol/L)
7·5 (0·6) 8·0 (1·0) –0·4 (–0·8 to –0·1) 0·0211
SD of glucose 
concentration (mmol/L)
2·5 (0·6) 3·2 (0·6) –0·7 (–1·0 to –0·4) <0·0001
Coefficient of variation 
of glucose concentration 
between nights (%)
24·9 (7·1) 34·4 (6·4) –9·6 (–13·2 to –5·9) <0·0001
Daytime (0601 h to 2359 h)
Proportion of time with glucose concentration in range (%)
3·9–10·0 mmol/L 74·3% (6·9) 66·1% (8·8) 8·1 (5·3 to 11·0) <0·0001
>10·0 mmol/L 22·2% (7·2) 27·9% (10·4) –5·6 (–8·9 to –2·3) 0·0023
<3·9 mmol/L 2·7% (1·9 to 4·5) 4·4% (2·8 to 8·6) 0·61 (0·49 to 0·76)† 0·0001
<3·5 mmol/L 1·2% (0·7 to 2·2) 2·3% (1·4 to 6·0) 0·47 (0·35 to 0·64)† <0·0001
<2·8 mmol/L 0·2% (0·1 to 0·5) 0·5% (0·2 to 1·3) 0·48 (0·29 to 0·80)† 0·0076
AUCday <3·5 mmol/L 
(mmol/L × min)
8·3 (3·4 to 14·3) 15·9 (7·5 to 45·7) 0·39 (0·25 to 0·86)† 0·0001
Mean glucose 
concentration (mmol/L)
8·0 (0·6) 8·4 (1·0) –0·3 (–0·6 to 0·0) 0·0498
SD of glucose 
concentration (mmol/L)
2·9 (0·4) 3·3 (0·6) –0·5 (–0·7 to –0·2) 0·0002
Coefficient of variation 
of glucose concentration 
between days (%)
13·8 (3·0) 20·6 (5·1) –6·8 (–9·1 to –4·6) <0·0001
Data are presented as mean (SD) or median (IQR), unless otherwise stated. No significant period effect was observed. 
AUCday=sensor glucose area under the curve per day. *Unless specified otherwise, data are normally distributed and 
presented as mean difference of closed-loop period minus control period, with 95% CI for mean; a positive value 
indicates that the measurement was higher in the closed-loop period than in the control period. †Non-normally 
distributed data are presented as ratio of closed-loop data over control data, with 95% CI for ratio; a value greater than 
unity indicates that the measurement was higher in the closed-loop period than in the control period. 
Table 4: Night-time and daytime glucose control during closed-loop and control periods based on sensor 
glucose measurements
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technologies striving to further improve control of their 
diabetes. We did not use remote monitoring or direct 
supervision, so as to adhere to real-world conditions. 
Additionally, we did not restrict the participants’ dietary 
habits, activity level, and geographical movements. 
However, we acknowledge that our study has several 
limitations. The relatively short study duration might 
have been insufficient to assess long-term compliance. 
We excluded participants with hypoglycaemia un-
awareness, therefore restricting assessment of the 
closed-loop system in those who might benefit greatly. 
The prototype nature of the closed-loop system and the 
number of devices might have increased the participants’ 
device burden and negatively affected some aspects of 
user feedback. The heterogeneity of sensor use in the 
control period might have confounded the reported 
glycaemic outcomes. However, the individualised therapy 
approaches used in the control period reflect present 
clinical strategies adopted by this population to achieve 
their baseline HbA1c, and do not diminish the incremental 
effects of closed-loop use.20
To conclude, day-and-night closed-loop insulin delivery 
in adults with type 1 diabetes and HbA1c below 7·5% 
significantly improved glycaemic control while reducing 
the risk of hypoglycaemia. Thus, in adults who are 
actively engaged with self-management, closed-loop 
insulin delivery might provide additional benefits, 
justifying its use in this particular population. The overall 
positive feedback from participants reflected the 
acceptance of closed-loop technology during daily 
diabetes management, albeit with some limitations to its 
use, which might affect user adherence and experience. 
Larger and longer studies are needed to validate our 
findings.
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